Okay, let's tackle this MCQ about drugs that increase bone formation in osteoporosis. The question is asking which drug does that. First, I need to recall the different classes of drugs used for osteoporosis.

Osteoporosis treatments are generally divided into antiresorptive agents and anabolic agents. Antiresorptives like bisphosphonates (e.g., alendronate) work by decreasing bone resorption. The anabolic agents, on the other hand, stimulate bone formation. The main one I remember is teriparatide, which is a recombinant human parathyroid hormone (PTH) fragment. It's supposed to increase bone formation by stimulating osteoblasts.

So the correct answer here should be teriparatide. Let me check the options again. The user didn't list the options, but assuming the options include teriparatide, that's the right choice. The other options might be bisphosphonates, calcitonin, or denosumab, which are antiresorptive. For example, bisphosphonates inhibit osteoclast activity, denosumab is a RANKL inhibitor, and calcitonin also inhibits bone resorption. None of these stimulate bone formation.

Wait, another anabolic agent is abaloparatide, which is a PTH-related protein analog. But if the options include teriparatide, that's the primary one. Also, romosozumab is a monoclonal antibody that acts on sclerostin, promoting bone formation. But it's less commonly mentioned compared to teriparatide. However, the question specifically says "bone formation is increased by which drug," so the answer is either teriparatide or romosozumab. But in standard exams, teriparatide is more commonly tested.

So the core concept here is distinguishing between drugs that stimulate bone formation versus those that inhibit resorption. The correct answer is the anabolic agent, which is teriparatide. The wrong options are all antiresorptives. The clinical pearl would be to remember that teriparatide is the anabolic drug for osteoporosis, while others like bisphosphonates just prevent loss.

**Core Concept**
Osteoporosis treatments are categorized into **antiresorptive agents** (e.g., bisphosphonates) and **anabolic agents** (e.g., teriparatide). Anabolic drugs stimulate bone formation via direct activation of osteoblasts, while antiresorptives inhibit osteoclast-mediated bone resorption.

**Why the Correct Answer is Right**
**Teriparatide**, a recombinant parathyroid hormone (PTH 1-34), acts as an anabolic agent. It stimulates osteoblast activity by binding to PTH receptors, increasing bone formation and reducing fracture risk. Unlike antiresorptives, it transiently elevates bone turnover but favors net bone gain during its short half-life (2-4 hours). It is FDA-approved for severe osteoporosis and administered subcutaneously.

**Why Each Wrong Option is Incorrect**
**Option A:** *Bisphosphonates* (e.g., alendronate) inhibit osteoclast activity, reducing bone resorption but not formation.
**Option B:** *Denosumab*

✓ Correct Answer: D. Teriparatide